… Gefitinib and erlotinib have been widely used to treat advanced NSCLC during the past
decade. By analyzing 40 high quality studies, we compared the antitumor effectiveness and …

… Forty-two patients with lung adenocarcinoma were reviewed in the present study. All … All
patients in the present study were affected by rash of some grade while receiving erlotinib. The …

… In these studies, concurrent administration of erlotinib or gefitinib with standard platinum-doublet
chemotherapy did not improve survival compared with chemotherapy alone. Preclinical …

… therapy were instructed to interrupt gefitinib treatment during treatment. Patients who required
… of separate clinical studies of single agent gefitinib and erlotinib in patients with BAC. …

… phase I study in Japan that suggested modest clinical activity of afatinib in such patients
following progression on erlotinib, gefitinib, or … while receiving erlotinib and/or gefitinib treatment. …

… consequences of receptor blockade were distinct in skin and tumor samples: while
phosphorylation of mitogen-activated protein kinase was inhibited in both tissues, gefitinib treatment …

… Ongoing studies are testing the concurrent use of gefitinib or erlotinib and an mTOR inhibitor,
such as Everolimus (Novartis Pharmaceuticals USA, East Hanover, NJ), in patients with …

… of therapy, this study identified a selected population of patients who achieved a median
of nearly 1 year of clinical benefit following failure of chemotherapy and gefitinib or erlotinib. …

… The randomized study (BR.21 study) brought erlotinib to registration by the US FDA on …
did not overlap with gefitinib treatment, which made the studies feasible. However, as expected, …

… gefitinib studies, 1 whereas the erlotinib study demonstrated a significant survival advantage
over the best supportive care … prospective biomarker study to evaluate erlotinib therapy in …